FI3750538T3 - (r)-silodosiinia käsittävät ei-hormonaaliset miesten ehkäisymenetelmät - Google Patents

(r)-silodosiinia käsittävät ei-hormonaaliset miesten ehkäisymenetelmät Download PDF

Info

Publication number
FI3750538T3
FI3750538T3 FIEP20182691.4T FI20182691T FI3750538T3 FI 3750538 T3 FI3750538 T3 FI 3750538T3 FI 20182691 T FI20182691 T FI 20182691T FI 3750538 T3 FI3750538 T3 FI 3750538T3
Authority
FI
Finland
Prior art keywords
composition
use according
silodosin
amount
male subject
Prior art date
Application number
FIEP20182691.4T
Other languages
English (en)
Finnish (fi)
Inventor
Glaoui Guillaume El
Glaoui Mehdi El
Philippe Perrin
Stéphane Droupy
Véronique Agathon-Meriau
Original Assignee
Pharmajor Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmajor Int filed Critical Pharmajor Int
Application granted granted Critical
Publication of FI3750538T3 publication Critical patent/FI3750538T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
FIEP20182691.4T 2018-03-23 2019-03-22 (r)-silodosiinia käsittävät ei-hormonaaliset miesten ehkäisymenetelmät FI3750538T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862763129P 2018-03-23 2018-03-23
EP18305328 2018-03-23

Publications (1)

Publication Number Publication Date
FI3750538T3 true FI3750538T3 (fi) 2024-09-24

Family

ID=65955198

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20182691.4T FI3750538T3 (fi) 2018-03-23 2019-03-22 (r)-silodosiinia käsittävät ei-hormonaaliset miesten ehkäisymenetelmät

Country Status (19)

Country Link
US (3) US10912762B2 (https=)
EP (2) EP3750538B1 (https=)
JP (1) JP7270901B2 (https=)
KR (1) KR102496504B1 (https=)
CN (1) CN112074269A (https=)
AU (1) AU2019237228B2 (https=)
BR (1) BR112020018925A2 (https=)
CA (1) CA3094016C (https=)
DK (2) DK3562485T3 (https=)
ES (2) ES2989170T3 (https=)
FI (1) FI3750538T3 (https=)
IL (1) IL277372B2 (https=)
MA (1) MA53626B1 (https=)
MX (1) MX2020009937A (https=)
PL (2) PL3562485T3 (https=)
PT (1) PT3562485T (https=)
SG (1) SG11202008794TA (https=)
UA (1) UA128502C2 (https=)
WO (1) WO2019180217A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3750538B1 (en) * 2018-03-23 2024-08-14 Pharmajor International Non-hormonal methods for male contraception comprising (r)-silodosin
IL319287A (en) 2022-11-23 2025-04-01 Pharmajor Incorporated Silodosin formulations with different release and their use in male contraceptive methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1091276A (en) 1911-12-09 1914-03-24 Basf Ag Producing unsaturated terpene hydrocarbons.
US4210644A (en) 1978-02-23 1980-07-01 The Johns Hopkins University Male contraception
DE4308406C1 (de) 1993-03-12 1994-06-16 Jenapharm Gmbh Kombinationspräparat zur Kontrazeption
ATE474580T1 (de) 2000-02-15 2010-08-15 Bayer Schering Pharma Ag Zusammensetzung zur männlichen kontrazeption, norethisteron enthaltend
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
UA95085C2 (ru) * 2005-09-29 2011-07-11 Баер Шеринг Фарма Акциенгезельшафт Применение варденафила для лечения урологических расстройств
JP2009509984A (ja) * 2005-09-29 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用のpde阻害剤およびそれらの組合せ
US20100098735A1 (en) * 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
GB0700893D0 (en) 2007-01-17 2007-02-21 King S College London Male contraceptive
MX2009009230A (es) 2007-02-28 2009-11-26 Kissei Pharmaceutical Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna.
US20120184591A1 (en) * 2011-01-13 2012-07-19 Watson Pharmaceuticals, Inc. Methods for treating prostatitis
CN102283816B (zh) * 2011-08-05 2013-09-11 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
WO2014118606A2 (en) * 2013-01-29 2014-08-07 Alembic Pharmaceuticals Limited A novel process for the preparation of silodosin
WO2016051782A1 (ja) 2014-09-30 2016-04-07 キッセイ薬品工業株式会社 苦味を有する薬剤の苦味をマスキングした経口投与製剤
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
EP3750538B1 (en) * 2018-03-23 2024-08-14 Pharmajor International Non-hormonal methods for male contraception comprising (r)-silodosin

Also Published As

Publication number Publication date
AU2019237228B2 (en) 2023-06-08
US10912762B2 (en) 2021-02-09
US11583518B2 (en) 2023-02-21
US20210113526A1 (en) 2021-04-22
NZ767741A (en) 2024-11-29
MX2020009937A (es) 2022-09-30
US11951095B2 (en) 2024-04-09
EP3562485A1 (en) 2019-11-06
RU2020134408A3 (https=) 2022-04-29
ES2989170T3 (es) 2024-11-25
JP7270901B2 (ja) 2023-05-11
US20230145374A1 (en) 2023-05-11
IL277372B1 (en) 2023-05-01
EP3562485B8 (en) 2020-08-19
PT3562485T (pt) 2020-08-27
BR112020018925A2 (pt) 2020-12-29
SG11202008794TA (en) 2020-10-29
RU2020134408A (ru) 2022-04-29
MA53626A (fr) 2022-03-09
EP3750538B1 (en) 2024-08-14
ES2813084T3 (es) 2021-03-22
AU2019237228A1 (en) 2020-10-01
CA3094016C (en) 2023-10-10
DK3562485T3 (da) 2020-08-24
EP3750538A1 (en) 2020-12-16
PL3750538T3 (pl) 2024-11-25
KR102496504B1 (ko) 2023-02-06
MA53626B1 (fr) 2024-09-30
WO2019180217A1 (en) 2019-09-26
UA128502C2 (uk) 2024-07-31
IL277372B2 (en) 2023-09-01
KR20200135978A (ko) 2020-12-04
CA3094016A1 (en) 2019-09-26
CN112074269A (zh) 2020-12-11
JP2021518438A (ja) 2021-08-02
IL277372A (en) 2020-11-30
PL3562485T3 (pl) 2020-11-16
DK3750538T3 (da) 2024-09-23
EP3562485B1 (en) 2020-07-01
US20190290615A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
US11807625B2 (en) Capsid inhibitors for the prevention of HIV
IT1271495B (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi
CA2626797A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
MX2025000291A (es) Compuesto heterocíclico capaz de inhibir prmt5•mta y uso del mismo
JP2022552187A5 (https=)
RU2015110470A (ru) Фармацевтическая композиция для местного нанесения, включающая тенофовир, антибактериальный агент и необязательно циклопирокс
CA2677691A1 (en) Reducing side effects of tramadol
FI3750538T3 (fi) (r)-silodosiinia käsittävät ei-hormonaaliset miesten ehkäisymenetelmät
CA2291160C (en) Combination therapy for modulating the human sexual response
MX2025011458A (es) Inhibidor de cyp11a1 y uso del mismo
JP7313438B2 (ja) Hivの予防のためのインテグラーゼ阻害剤
JP2002522388A (ja) 性機能障害の治療のためのピリジノン
JP2021518438A5 (https=)
KR101634382B1 (ko) 타다라필 경구용 액제
US20100311785A1 (en) Combination Therapy For Modulating The Human Sexual Response
US20110224178A1 (en) Composition and method for treating erectile dysfunction
US9610295B2 (en) Method for treating erectile dysfunction
NZ767741B2 (en) Non-hormonal compositions and methods for male contraception
US12186325B2 (en) Treatment and prevention of premature ejaculation (PE)
US20170157128A1 (en) Method for treating erectile dysfunction
HK40071778A (zh) 用於预防hiv的衣壳抑制剂
RU2021137713A (ru) Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона
HK40053063A (en) Treatment and prevention of premature ejaculation (pe)
HK40053063B (en) Treatment and prevention of premature ejaculation (pe)
RU2015139210A (ru) Твердая пероральная фармацевтическая композиция S1P-агониста или его фармацевтически приемлемой соли, способы ее получения и способы лечения и снижения частоты клинических обострений рассеянного склероза